Health care resource utilization of patients with asthma and food allergy initiating omalizumab
FA-related, asthma/FA-related, and all-cause emergency department visits and hospitalizations significantly reduced in the 12 months after omalizumab initiation. These results provide valuable and timely real-world evidence that omalizumab has the potential to reduce the acute care utilization in patients with comorbid asthma and FA.
Authors
- Riddhi Doshi (ORCID: https://orcid.org/0000-0002-1439-1511)
- E. Wang
- J. Andrew Bird
- Julie Wang (ORCID: https://orcid.org/0000-0001-5956-0123)
- David M. Fleischer (ORCID: https://orcid.org/0000-0001-7358-384X)
- Vincent Garmo (ORCID: https://orcid.org/0000-0003-3073-0373)
- Sachin Gupta (ORCID: https://orcid.org/0000-0002-2407-5555)
- Aimee M. Near (ORCID: https://orcid.org/0000-0001-9423-8244)
- Arpamas Seetasith (ORCID: https://orcid.org/0000-0003-0648-7764)
- Xiaohui Zhao (ORCID: https://orcid.org/0000-0003-3953-9110)
- Stella Ko
Institutions
- Southwestern Medical Center (US)
- IQVIA (United States) (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1016/j.jacig.2025.100491
- Primary Topic
- Food Allergy and Anaphylaxis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Genentech